NewLimit
Backed by
NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.
Senior/Research Associate, Metabolism
South San Francisco · Posted on Oct 8, 2025
Scientist/Senior Scientist, Vascular
South San Francisco, CA · Posted on Oct 8, 2025
Scientist/Senior Scientist, Functional Genomics
South San Francisco, CA · Posted on Oct 7, 2025
Scientist, Lipid Nanoparticle Delivery
South San Francisco, CA · Posted on Oct 7, 2025
Vivarium Technician
South San Francisco · Posted on Oct 7, 2025
Senior/Research Associate, Single Cell Genomics
South San Francisco, CA · Posted on Sep 15, 2025
Scientist/Senior Scientist, Immunology
South San Francisco, CA · Posted on Aug 27, 2025
Senior/Research Associate, Functional Genomics
South San Francisco, CA · Posted on Jun 23, 2025
Group Leader, Immunology
South San Francisco, CA · Posted on Apr 21, 2025
Explore similar companies to NewLimit
Convoke
AI-native OS for drug development.
Cradle
Engineer better proteins, faster.
Periodic Labs
Creating an AI scientist.
Nudge
Whole-brain interfaces for everyday life.
Manifold Bio
Tissue-targeted medicines, designed in vivo.
Science
A brighter tomorrow enabled by neural engineering.
Until
Developing reversible cryopreservation.
Loyal
Extending the lifespan of dogs.
Salt
AI for life sciences.